Targeted expression of BikDD eliminates breast cancer with virtually no toxicity in noninvasive imaging models

Molecular Cancer Therapeutics

Volumn 11, Issue 9, 2012, Pages 1915-1924

  Xie, Xinhua ^a   Li, Laisheng ^a   Xiao, Xiangsheng ^a   Guo, Jiaoli ^a   Kong, Yanan ^a   Wu, Minqing ^a   Liu, Wanli ^a   Gao, Guoquan ^b   Hsu, Jennifer L ^c   Wei, Dong ^a   Hung, Mien Chie ^c   Xie, Xiaoming ^a  

^a SUN YAT SEN UNIVERSITY CANCER CENTER   (China)

^b SUN YAT SEN UNIVERSITY   (China)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NANOPARTICLE; PROTEIN VP16; T VISA BIKDD NANOPARTICLE; TELOMERASE REVERSE TRANSCRIPTASE; TRANSCRIPTION FACTOR GAL4; UNCLASSIFIED DRUG;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CANCER CELL; CANCER INHIBITION; CELL GROWTH; CONTROLLED STUDY; CYTOMEGALOVIRUS; DRUG SPECIFICITY; FEMALE; GENE EXPRESSION; GENE TARGETING; HUMAN; HUMAN CELL; IMAGING; ISOGRAFT; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROMOTER REGION; SURVIVAL TIME; TRANSGENICS; TUMOR XENOGRAFT; VIRAL GENE DELIVERY SYSTEM;

ANIMALS; APOPTOSIS; APOPTOSIS REGULATORY PROTEINS; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE TRANSFER TECHNIQUES; GENES, REPORTER; GENETIC THERAPY; HUMANS; LUCIFERASES, FIREFLY; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; MICE, NUDE; NANOPARTICLES; NEOPLASM TRANSPLANTATION; PROMOTER REGIONS, GENETIC; TELOMERASE; TRANSGENES; TUMOR BURDEN;

EID: 84866091549     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-0191     Document Type: Article

References (30)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin 2012;62:10-29.
2. Burstein HJ, Winer EP. Refining therapy for human epidermal growth factor receptor 2-positive breast cancer: T stands for trastuzumab, tumor size, and treatment strategy. J Clin Oncol 2009;27:5671-3.
3. Tutt A, Robson M, Garber JE, Domchek SM, Audeh MW, Weitzel JN, et al. Oral poly(ADP-ribose) polymerase inhibitor olaparib in patients with BRCA1 or BRCA2 mutations and advanced breast cancer: a proof-of-concept trial. Lancet 2010;376:235-44.
4. Ellisen LW. PARP inhibitors in cancer therapy: promise, progress, and puzzles. Cancer Cell 2011;19:165-7.
5. Lee M. Hypoxia targeting gene expression for breast cancer gene therapy. Adv Drug Deliv Rev 2009;61:842-9.
6. Chanda D, Isayeva T, Kumar S, Siegal GP, Szafran AA, Zinn KR, et al. Systemic osteoprotegerin gene therapy restores tumor-induced bone loss in a therapeutic model of breast cancer bone metastasis. Mol Ther 2008;16:871-8. (Pubitemid 351587096)
7. Xie X, Guo J, Kong Y, Xie GX, Li L, Lv N, et al. Targeted expression of E. coli purine nucleoside phosphorylase and Fludara for prostate cancer therapy. J Gene Med 2011;13:680-91.
8. Li J, Huang L. Targeted delivery of RNAi therapeutics for cancer therapy. Nanomedicine (Lond) 2010;5:1483-6.
9. Chen Y, Zhu X, Zhang X, Liu B, Huang L. Nanoparticles modified with tumor-targeting scFv deliver siRNA and miRNAfor cancer therapy. Mol Ther 2010;18:1650-6.
10. Russ V, Wagner E. Cell and tissue targeting of nucleic acids for cancer gene therapy. Pharm Res 2007;24:1047-57. (Pubitemid 46798888)
11. Hyun H, Won YW, Kim KM, Lee J, Lee M, Kim YH. Therapeutic effects of a reducible poly (oligo-D-arginine) carrier with the heme oxygenase-1 gene in the treatment of hypoxic-ischemic brain injury. Biomaterials 2010;31:9128-34.
12. Pi Y, Zhang X, Shi J, Zhu J, Chen W, Zhang C, et al. Targeted delivery of non-viral vectors to cartilage in vivo using a chondrocyte-homing peptide identified by phage display. Biomaterials 2011;32:6324-32.
13. Xie X, Xia W, Li Z, Kuo HP, Liu Y, Li Z, et al. Targeted expression of BikDD eradicates pancreatic tumors in noninvasive imaging models. Cancer Cell 2007;12:52-65. (Pubitemid 47001785)
14. Lang JY, Hsu JL, Meric-Bernstam F, Chang CJ, Wang Q, Bao Y, et al. BikDD eliminates breast cancer initiating cells and synergizes with lapatinib for breast cancer treatment. Cancer Cell 2011;20:341-56.
15. Xie X, Hsu JL, Choi MG, Xia W, Yamaguchi H, et al. A novel hTERT promoter-driven E1A therapeutic for ovarian cancer. Mol Cancer Ther 2009;8:2375-82.
16. Sher YP, Tzeng TF, Kan SF, Hsu J, Xie X, Han Z, et al. Cancer targeted gene therapy of BikDD inhibits orthotopic lung cancer growth and improves long-term survival. Oncogene 2009;28:3286-95.
17. Elkak AE, Meligonis G, Salhab M, Mitchell B, Blake JR, Newbold RF, et al. hTERT protein expression is independent of clinicopathological parameters and c-Myc protein expression in human breast cancer. J Carcinog 2005;4:17.
18. Hu Z, Robbins JS, Pister A, Zafar MB, Zhang ZW, Gupta J, et al. A modified hTERT promoter-directed oncolytic adenovirus replication with concurrent inhibition of TGFbeta signaling for breast cancer therapy. Cancer Gene Ther 2010;17:235-43.
19. Garg H, Salcedo R, Trinchieri G, Blumenthal R. Improved nonviral cancer suicide gene therapy using survivin promoter-driven mutant Bax. Cancer Gene Ther 2010;17:155-63.
20. Peng XH, Karna P, Cao Z, Jiang BH, Zhou M, Yang L. Cross-talk between epidermal growth factor receptor and hypoxia-inducible factor-1alpha signal pathways increases resistance to apoptosis by up-regulating survivin gene expression. J Biol Chem 2006;281:25903-14. (Pubitemid 44401796)
21. Kulka J, Szasz AM, Nemeth Z, Madaras L, Schaff Z, Molnar IA, et al. Expression of tight junction protein claudin-4 in basal-like breast carcinomas. Pathol Oncol Res 2009;15:59-64.
22. Lanigan F, McKiernan E, Brennan DJ, Hegarty S, Millikan RC, McBryan J, et al. Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer. Int J Cancer 2009;124:2088-97.
23. Szasz AM, Nemeth Z, Gyorffy B, Micsinai M, Krenacs T, Baranyai Z, et al. Identification of a claudin-4 and E-cadherin score to predict prognosis in breast cancer. Cancer Sci 2011;102:2248-54.
24. Jin Q, Yuan LX, Boulbes D, Baek JM, Wang YN, Gomez-Cabello D, et al. Fatty acid synthase phosphorylation: a novel therapeutic target in HER2-overexpressing breast cancer cells. Breast Cancer Res 2010;12:R96.
25. Yoon S, Lee MY, Park SW, Moon JS, Koh YK, Ahn YH, et al. Up-regulation of acetyl-CoA carboxylase alpha and fatty acid synthase by human epidermal growth factor receptor 2 at the translational level in breast cancer cells. J Biol Chem 2007;282:26122-31. (Pubitemid 47443806)
26. Gu W, Pan F, Singer RH. Blocking beta-catenin binding to the ZBP1 promoter represses ZBP1 expression, leading to increased proliferation and migration of metastatic breast-cancer cells. J Cell Sci 2009;122:1895-905.
27. Li YM, Wen Y, Zhou BP, Kuo HP, Ding Q, Hung MC. Enhancement of Bik antitumor effect by Bik mutants. Cancer Res 2003;63:7630-3. (Pubitemid 37466686)
28. Day CP, Rau KM, Qiu L, Liu CW, Kuo HP, Xie X, et al. Mutant Bik expression mediated by the enhanced minimal topoisomerase IIalpha promoter selectively suppressed breast tumors in an animal model. Cancer Gene Ther 2006;13:706-19. (Pubitemid 44264474)
29. Templeton NS, Lasic DD, Frederik PM, Strey HH, Roberts DD, Pavlakis GN. Improved DNA:liposome complexes for increased systemic delivery and gene expression. Nat Biotechnol 1997;15:647-52. (Pubitemid 27291165)
30. Li LY, Dai HY, Yeh FL, Kan SF, Lang J, Hsu JL, et al. Targeted hepatocellular carcinoma proapoptotic BikDD gene therapy. Oncogene 2011;30:1773-83.